Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 13, 2025 | -$0.14 | -$0.13 | Beat |
| Aug 13, 2025 | -$0.17 | -$0.15 | Beat |
| May 13, 2025 | -$0.18 | -$0.15 | Beat |
| Apr 14, 2025 | -$0.18 | $0.52 | Beat |
| Nov 7, 2024 | -$0.16 | -$0.48 | Miss |
| Aug 7, 2024 | -$0.16 | -$0.13 | Beat |